Skip to content
The Kids Research Institute Australia logo
Donate

Search

Showing results for "clinical trials"

Suicide by young Australians, 2006-2015: a cross-sectional analysis of national coronial data

Objective: To assess the demographic, social, and clinical characteristics of young Australians who die by suicide.

Toxoplasma gondii, Herpesviridae and long-term risk of transition to first-episode psychosis in an ultra high-risk sample

Ultra high-risk (UHR) criteria were introduced to identify people at imminent risk of developing psychosis. To improve prognostic accuracy, additional clinical and biological risk factors have been researched.

WATCH: Cultural safety brings community together at Boola Bardip

Barry Winmar began proceedings with a Welcome to Country and smoking ceremony.

Epidemiology of gastrostomy insertion for children and adolescents with intellectual disability

Gastrostomy is increasingly used in multiple neurological conditions associated with intellectual disability, with no apparent accessibility barriers

Causal Impact of COVID-19 Lockdowns on the Mental Health of Australian Children

This project investigates the prevalence, risk factors, and causal impact of COVID-19 lockdowns on mental health disorders, self-harm, and suicide among Australian children.

Understanding motivation and experience in participating in a paediatric SARS-CoV-2 serosurvey, in Australia

Serosurveys are considered as a valuable tool in estimating population immunity and infection rates but recruitment of children to provide paediatric estimates can be challenging. A novel approach of sampling children undergoing anaesthesia was utilised for a SARS-CoV-2 serosurvey in Australian children and we explore the reasons for participation, feedback on the approach and importance of research into Coronavirus Diseases 2019 (COVID-19).

Severity of Rotavirus-Vaccine-Associated Intussusception: Prospective Hospital-Based Surveillance, Australia, 2007-2018

Multiple studies have shown an association between intussusception (IS) and receipt of monovalent or pentavalent rotavirus vaccine (RV) in the previous 21 days. Disease severity is an important consideration for risk-benefit evaluations of RV, but no studies have compared the severity of IS within 21 days of vaccination (vaccine-associated, VA) and later (not temporally-associated, VNA).

4CMenB vaccine and its role in preventing transmission and inducing herd immunity

Vaccination is the most effective method of protecting people from invasive meningococcal disease (IMD). Of all the capsular groups, B is the most common cause of invasive meningococcal disease in many parts of the world. Despite this, adolescent meningococcal B vaccine programs have not been implemented globally, partly due to the lack of evidence for herd immunity afforded by meningococcal B vaccines.

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.